Tearsheet

Sight Sciences (SGHT)

Market Price (12/4/2025): $8.42 | Market Cap: $441.0 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Sight Sciences (SGHT)

Market Price (12/4/2025): $8.42
Market Cap: $441.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%	Trading close to highs Dist 52W High is 0.0%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -60%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management.	Weak multi-year price returns 3Y Excs Rtn is -91%	Stock price has recently run up significantly 6M Rtn6 month market price return is 102%, 12M Rtn12 month market price return is 122%
2			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.4%, Rev Chg QQuarterly Revenue Change % is -1.2%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -41%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42%
4			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50%
5			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management.
2	Trading close to highs Dist 52W High is 0.0%
3	Weak multi-year price returns 3Y Excs Rtn is -91%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -60%
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 102%, 12M Rtn12 month market price return is 122%
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.4%, Rev Chg QQuarterly Revenue Change % is -1.2%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -41%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42%
8	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30%

Valuation, Metrics & Events

	12/4/25	2024	2023	2022	2021
Share Price CYE	$8.42	$3.64	$5.16	$12.21	$17.57
Market Cap CYE ($ Mil)	441.0	184.9	252.3	588.6	834.7
Total Debt ($ Mil)	40.7	40.4	35.4	35.0	34.2
Total Cash ($ Mil)	92.4	120.4	138.1	185.0	260.7
Enterprise Value ($ Mil)	389.3	225.3	287.7	623.6	868.9
Valuation Ratios
P/S TTM	2.3	2.3	3.1	8.2	9.6
P/EBIT TTM	-4.3	-3.9	-5.0	-7.2	-8.0
P/E TTM	-3.8	-3.5	-4.5	-6.8	-7.5
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9	4.4	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.2	-2.6
P/E TTM (Sector)	-1.6	-1.5	-1.5	-1.3	-2.8

	12/4/25	2024	2023
Share Price CYE	$8.42	$3.64	$5.16
Market Cap CYE ($ Mil)	441.0	184.9	252.3
Total Debt ($ Mil)	40.7	40.4	35.4
Total Cash ($ Mil)	92.4	120.4	138.1
Enterprise Value ($ Mil)	389.3	225.3	287.7
Valuation Ratios
P/S TTM	2.3	2.3	3.1
P/EBIT TTM	-4.3	-3.9	-5.0
P/E TTM	-3.8	-3.5	-4.5
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.6	-1.5	-1.5

	SGHT	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.1
Rev Chg Q	-1.2%	7.1%
Rev Chg LTM	-4.4%	6.1%
Rev Chg 3Y Avg	6.1%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-59.6%	18.8%
CFO/Rev LTM	-41.2%	20.5%
Net Inc Mgn	-60.6%	13.1%
VALUATION	MODERATE
P/S	2.3	3.2
P/CFO	-5.7	15.8
P/FCF	-5.6	20.5
P/E	-3.8	23.5
STABILITY	VERY GOOD
Debt/Equity	0.23	0.20
Cash/Assets	0.79	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Surgical Glaucoma ordering accounts	1197	9302025	Link

Recent
11/06/2025	Earnings Release	Rev: $19 Mil (A) vs. $20 Mil (E) EPS: -0.16 (A) vs. $-0.26 (E)
Upcoming
3/04/2026	Earnings Release	Rev: - EPS: -

SGHT Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

1. Sight Sciences reported strong third-quarter 2025 financial results and increased its full-year 2025 revenue guidance. The company generated $19.9 million in total revenue for Q3 2025 and, more notably, raised its full-year 2025 revenue guidance to a range of $76.0 million to $78.0 million, up from the prior guidance of $72.0 million to $76.0 million. This revised outlook suggests improved performance expectations for the remainder of the year. Additionally, the company reduced its adjusted operating expense guidance for full year 2025.

2. Favorable reimbursement decisions were made for the TearCare interventional dry eye procedure. Two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options, established fee schedules that include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure. These MACs cover approximately 30% of the total estimated Medicare lives, representing a significant step towards broader reimbursed market access for Sight Sciences' dry eye segment.

3. The Surgical Glaucoma segment demonstrated growth and positive clinical backing. The company's Surgical Glaucoma revenue increased by 6% compared to the prior year's third quarter, and ordering accounts for this segment reached an all-time high of 1,197, an 8% increase from Q3 2024. Furthermore, a systematic literature review and meta-analysis published in the Journal of Glaucoma showed that the OMNI Surgical System achieved clinically significant, long-term reductions in intraocular pressure (IOP) and medication use for open-angle glaucoma patients.

4. Operating expenses were reduced, signaling a focus on efficiency. Sight Sciences successfully reduced total operating expenses to $25.1 million in the third quarter of 2025, an 11% decrease compared to the same period in the prior year. This reduction included $2.8 million in restructuring costs associated with a reduction in force announced in August 2025, which is projected to yield approximately $12 million in annualized personnel-related savings.

5. Key executive leadership appointments were made. Effective November 5, 2025, Sight Sciences appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer. Ms. Bauerlein, previously CFO at Inogen, is noted for her strong track record in scaling companies, which could be viewed positively by investors.

Show less

Stock Movement Drivers

Fundamental Drivers

The 125.3% change in SGHT stock from 9/3/2025 to 12/3/2025 was primarily driven by a 128.4% change in the company's P/S Multiple.

	9032025	12032025	Change
Stock Price ($)	3.80	8.56	125.26%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	76.30	76.05	-0.33%
P/S Multiple	2.58	5.90	128.43%
Shares Outstanding (Mil)	51.82	52.38	-1.07%
Cumulative Contribution			125.24%

LTM = Last Twelve Months as of date shown

Market Drivers

9/3/2025 to 12/3/2025

	Return	Correlation
SGHT	125.3%
Market (SPY)	6.2%	37.4%
Sector (XLV)	13.3%	33.1%

Fundamental Drivers

The 101.9% change in SGHT stock from 6/4/2025 to 12/3/2025 was primarily driven by a 111.7% change in the company's P/S Multiple.

	6042025	12032025	Change
Stock Price ($)	4.24	8.56	101.89%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	78.11	76.05	-2.63%
P/S Multiple	2.78	5.90	111.74%
Shares Outstanding (Mil)	51.29	52.38	-2.12%
Cumulative Contribution			101.80%

LTM = Last Twelve Months as of date shown

Market Drivers

6/4/2025 to 12/3/2025

	Return	Correlation
SGHT	101.9%
Market (SPY)	15.1%	40.5%
Sector (XLV)	16.9%	34.5%

Fundamental Drivers

The 121.8% change in SGHT stock from 12/3/2024 to 12/3/2025 was primarily driven by a 141.3% change in the company's P/S Multiple.

	12032024	12032025	Change
Stock Price ($)	3.86	8.56	121.76%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	79.54	76.05	-4.39%
P/S Multiple	2.44	5.90	141.33%
Shares Outstanding (Mil)	50.34	52.38	-4.05%
Cumulative Contribution			121.40%

LTM = Last Twelve Months as of date shown

Market Drivers

12/3/2024 to 12/3/2025

	Return	Correlation
SGHT	121.8%
Market (SPY)	14.3%	33.5%
Sector (XLV)	7.0%	26.9%

Fundamental Drivers

The -28.2% change in SGHT stock from 12/4/2022 to 12/3/2025 was primarily driven by a -32.5% change in the company's P/S Multiple.

	12042022	12032025	Change
Stock Price ($)	11.93	8.56	-28.25%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	65.47	76.05	16.16%
P/S Multiple	8.73	5.90	-32.47%
Shares Outstanding (Mil)	47.91	52.38	-9.32%
Cumulative Contribution			-28.87%

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2023 to 12/3/2025

	Return	Correlation
SGHT	193.2%
Market (SPY)	53.2%	30.4%
Sector (XLV)	20.8%	24.3%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SGHT Return	-	-	-31%	-58%	-29%	128%	-53%
Peers Return	52%	3%	-11%	-6%	-18%	41%	52%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	112%
Monthly Win Rates [3]
SGHT Win Rate	-	20%	58%	33%	42%	50%
Peers Win Rate	50%	42%	40%	35%	31%	53%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
SGHT Max Drawdown	-	-	-68%	-89%	-35%	-43%
Peers Max Drawdown	-31%	-15%	-31%	-31%	-27%	-13%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: A, ATEC, CERS, AVRT, BLLN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

Unique Key	Event	SGHT	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-96.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	2931.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to A, ATEC, CERS, AVRT, BLLN

In The Past

Sight Sciences's stock fell -96.7% during the 2022 Inflation Shock from a high on 8/9/2021. A -96.7% loss requires a 2931.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Sight Sciences (SGHT)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

AI Generated Analysis | Feedback

A Glaukos for comprehensive minimally invasive glaucoma surgery and therapeutic dry eye devices.
A Dexcom for innovative devices treating chronic eye conditions like glaucoma and dry eye.

AI Generated Analysis | Feedback

```html

OMNI Surgical System: A minimally invasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
TearCare System: A wearable device that delivers localized heat to the eyelids for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD).

```

AI Generated Analysis | Feedback

Sight Sciences (SGHT) sells primarily to other companies within the healthcare sector, making it a business-to-business (B2B) operation.

Due to the nature of the medical device market and Sight Sciences' sales strategy, the company does not typically disclose specific individual "major customer companies" (e.g., large hospital chains or purchasing groups) that account for a material portion of its revenue in its public filings. This is common for medical device manufacturers, as their sales are often distributed across a broad base of healthcare providers rather than concentrated with a few large entities. In fact, Sight Sciences states in its public filings that it does not believe the loss of any single customer would have a material adverse effect on its business because it has a large number of customers.

Sight Sciences' products, such as the OMNI Surgical System (for glaucoma) and the TearCare System (for dry eye disease), are sold to a fragmented market of ophthalmic professionals and facilities. Therefore, its primary customer categories are:

Ophthalmology Practices: Individual or group practices specializing in eye care, where ophthalmologists perform surgical procedures for glaucoma and in-office treatments for dry eye disease.
Ambulatory Surgical Centers (ASCs): Outpatient facilities where ophthalmic surgical procedures, including those utilizing Sight Sciences' OMNI Surgical System, are performed.
Hospitals: Healthcare institutions that have ophthalmology departments or surgical units performing eye-related procedures.
Optometry Practices: Practices where optometrists manage and treat dry eye disease, often utilizing the TearCare System.

In international markets, Sight Sciences also utilizes third-party distributors who then sell its products to similar healthcare providers and facilities.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Paul Badawi, Founder, Chief Executive Officer

Paul Badawi is a co-founder of Sight Sciences, Inc. and has served as its President, CEO, and Director since the company's founding in 2011. Prior to launching Sight Sciences, he led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm, where he managed a portfolio of 12 medical device investments. While at 3i Group, he served as a lead investor and board member for companies such as Ulthera (acquired by Merz), Xthetix (acquired by Johnson & Johnson), and NeoGuide (acquired by Intuitive Surgical), among others. He holds an MBA from the University of California, Los Angeles, and a BS in Biological Sciences from the University of Chicago.

James Rodberg, Chief Financial Officer

James Rodberg was appointed Chief Financial Officer of Sight Sciences, effective November 5, 2025. He joined Sight Sciences in early 2021 as Vice President of Finance and Corporate Controller and also served as interim CFO in 2023. His previous experience includes roles at nVent Electric, Abbott Laboratories, and St. Jude Medical, where he held increasingly senior finance and accounting positions prior to St. Jude Medical's acquisition by Abbott. Rodberg has 20 years of experience in public accounting and company finance leadership.

Alison Bauerlein, Chief Operating Officer

Alison Bauerlein was named Chief Operating Officer of Sight Sciences, a newly created position, effective November 5, 2025, succeeding herself as CFO. She joined Sight Sciences in April 2023 as CFO. Prior to Sight Sciences, Bauerlein co-founded Inogen, a medical technology company, where she served as CFO from 2009 to 2021. During her tenure at Inogen, she was instrumental in scaling the company from a startup to over $350 million in annual sales. She brings experience leading global finance and accounting functions, investor relations, and business development.

David Badawi, Founder, Chief Technology Officer

David Badawi is a co-founder and Chief Technology Officer of Sight Sciences. He is the brother of CEO Paul Badawi. He is also a co-inventor of several of the company's key products, including the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.

Sam Park, Chief Operating Officer

Sam Park joined Sight Sciences as Chief Operating Officer in June 2020. He brings over 25 years of medical device experience, including executive-level leadership roles at several companies that were subsequently acquired. These include SurgRx (acquired by Johnson & Johnson's Ethicon Endo-Surgery division), Novacept (acquired by Cytyc), Arthrocare (acquired by Smith+Nephew), Origin Medsystems (acquired by Eli Lily and Company), and CardioGenesis (acquired by CryoLife).

AI Generated Analysis | Feedback

The recent market entry of novel pharmacological treatments for evaporative dry eye disease poses an emerging threat to Sight Sciences' TearCare System. For example, Bausch + Lomb's Miebo (perfluorohexyloctane ophthalmic solution), approved by the FDA in May 2023, offers a new mechanism of action to reduce tear evaporation, a primary symptom addressed by treating meibomian gland dysfunction (MGD) with devices like TearCare. While TearCare directly treats MGD, a leading cause of evaporative dry eye, a highly effective and easily administered eye drop like Miebo could potentially capture a segment of the market, reduce the perceived need for device-based interventions for some patients, or alter the treatment pathway, thus impacting the adoption and market share of the TearCare System.

AI Generated Analysis | Feedback

Sight Sciences (SGHT) focuses on two main product areas: surgical glaucoma and dry eye disease.

Surgical Glaucoma Products (OMNI Surgical System, SION Surgical Instrument)

Sight Sciences' OMNI Surgical System and SION Surgical Instrument address the Minimally Invasive Glaucoma Surgery (MIGS) market.

The global minimally invasive glaucoma surgery (MIGS) devices market was estimated at USD 539.6 million in 2023 and is anticipated to grow to USD 781.2 million by 2030, with a compound annual growth rate (CAGR) of 5.36% from 2024 to 2030.
Another estimate projects the global MIGS devices market to reach approximately USD 1.8 billion in 2025 and expand at a CAGR of around 20% through 2033.
For the U.S. market, the total addressable market for Combination Cataract MIGS is approximately USD 1 billion, and for Standalone MIGS, it is nearly USD 5 billion.
North America held the largest share (36%) of the MIGS devices market in 2023.

Dry Eye Disease Products (TearCare System)

The TearCare System from Sight Sciences addresses the dry eye disease (DED) market, specifically evaporative dry eye disease due to meibomian gland dysfunction (MGD).

The global dry eye disease treatment market is valued at USD 6.36 billion in 2025 and is forecast to reach USD 7.77 billion by 2030, with a CAGR of 4.09%.
Another projection estimates the global market for dry eye syndrome therapeutics to reach USD 8.5 billion by 2033, growing at a CAGR of 4.5% over the forecast period.
The dry eye disease market size was valued at over USD 6 billion in 2022 and is projected to reach around USD 12.3 billion by 2032.
In North America, the dry eye disease market was valued at USD 2.4 billion in 2022. The United States has the largest patient pool for dry eye disease and represents the biggest market for its treatment.

AI Generated Analysis | Feedback

Sight Sciences (SGHT) anticipates several key drivers to fuel its revenue growth over the next 2-3 years:

Accelerated Commercialization of TearCare with Reimbursed Market Access: A significant driver is the expanded Medicare coverage for the TearCare System. The establishment of jurisdiction-wide pricing with First Coast Service Options and Novitas Solutions, covering 10.4 million Medicare beneficiaries, is expected to enable Sight Sciences to pioneer the reimbursed market for interventional dry eye procedures. The company is actively focusing on accelerating commercialization efforts in these newly covered regions.
Continued Growth of the OMNI Surgical System in Glaucoma: The Surgical Glaucoma segment, driven by the OMNI Surgical System, demonstrated a 6% revenue increase in Q3 2025, propelled by an increase in ordering accounts and average selling prices. Management projects sustained growth for OMNI in both combination cataract and standalone use cases throughout 2025 and into 2026, emphasizing its differentiated clinical profile.
Expansion of Ordering Accounts and Increased Product Utilization: For the Surgical Glaucoma segment, the number of ordering accounts reached a record high, indicating growing market penetration. The company's strategy involves strengthening commercial execution and driving further adoption of its OMNI technology. For TearCare, the focus is on education, identification, and activation of accounts in new jurisdictions with established reimbursement, aiming to substantially increase utilization.
Launch of Next-Generation OMNI: Sight Sciences has a robust pipeline of interventional glaucoma and dry eye technologies, including the planned release of a next-generation OMNI product in the first half of 2025. This new product introduction is expected to contribute to future revenue growth by offering enhanced solutions to the market.
Advancement of Clinical Data and Market Development for TearCare: The anticipated publication of clinical data and a budget impact model for TearCare is expected to accelerate its adoption and growth in 2025. Furthermore, the inclusion of the TearCare System in global dry eye guidelines is a significant milestone that supports broader market acceptance and access.

AI Generated Analysis | Feedback

Share Issuance

In July 2021, Sight Sciences completed its Initial Public Offering (IPO), issuing 11,500,000 shares of common stock at an initial public offering price of $24.00 per share.
The IPO generated approximately $276 million in gross proceeds.

Inbound Investments

Sight Sciences closed an over $30 million Series E Preferred Stock financing round in March 2020, led by D1 Capital Partners.
A Series E round on December 3, 2020, brought in an additional $23.2 million, with Janus Henderson Investors as the lead investor.

Capital Expenditures

Sight Sciences reported capital expenditures of $210,000 for the quarter ending June 2025.

Better Bets than Sight Sciences (SGHT)

	SGHT	Better Performance than SGHT
Metric	Value	INDUSTRY: Life Sciences Tools & Services
Rev Chg LTM	-4.4%	NTRA (38.2%), A (4.5%), IQV (3.8%), TMO (3.2%), DHR (2.2%)
Rev Chg 3Y Avg	6.1%	NTRA (40.2%), GH (28.0%), IRTC (22.8%), MEDP (19.9%), EXAS (15.5%)
Op Mgn LTM	-59.6%	A (21.3%), DHR (19.0%), TMO (18.4%), IQV (14.2%), NTRA (-16.6%)
CFO/Rev LTM	-41.2%	DHR (26.0%), A (22.0%), IQV (17.6%), TMO (17.5%), NTRA (9.2%)
FCF/Rev LTM	-41.6%	DHR (20.7%), A (16.0%), TMO (14.0%), IQV (13.9%), NTRA (4.4%)
Total Yield	-25.6%	A (4.5%), IQV (4.0%), TMO (3.6%), DHR (2.5%), NTRA (-1.4%)
P/S	2.4	AVTR (1.3), CRL (1.9), IQV (2.0), AZTA (2.1), NVCR (2.3)
P/Op Inc	-4.0

	SGHT	Better Performance than SGHT
Metric	Value	SECTOR: Health Care
Rev Chg LTM	-4.4%	LLY (36.8%), UNH (10.5%), ABBV (7.4%), JNJ (5.1%), MRK (1.7%)
Rev Chg 3Y Avg	6.1%	LLY (23.4%), ISRG (16.3%), UNH (11.4%), AMGN (11.2%), JNJ (6.1%)
Op Mgn LTM	-59.6%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-41.2%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-41.6%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-25.6%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	2.4	MCK (0.2), UNH (0.7), HCA (1.4), BMY (1.9), PFE (2.3)
P/Op Inc	-4.0

	SGHT	Better Performance than SGHT
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	-4.4%	NVDA (71.6%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Rev Chg 3Y Avg	6.1%	NVDA (92.0%), AVGO (24.0%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%)
Op Mgn LTM	-59.6%	NVDA (58.1%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-41.2%	MSFT (50.0%), NVDA (46.6%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-41.6%	NVDA (43.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-25.6%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/S	2.4	WMT (1.1), XOM (1.4), COST (1.5), CVX (1.6), HD (2.2)
P/Op Inc	-4.0

		Best Bets In Health Care Sector
	SGHT
What You Pay
P/E	-3.9
P/EBIT	-4.4
What You Get
Rev Chg Q	-1.2%
Rev Chg LTM	-4.4%
Rev Chg 3Y Avg	6.1%
FCF/Rev 3Y Avg	-47.6%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Would You Still Hold Sight Sciences Stock If It Fell 30%?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to SGHT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.3	223.6%	367.4%
COGT	Cogent Biosciences	5.4	152.6%	402.1%
CDTX	Cidara Therapeutics	5.9	115.1%	722.1%
IRWD	Ironwood Pharmaceuticals	0.6	100.5%	-15.8%
TERN	Terns Pharmaceuticals	2.5	95.9%	396.2%
FRGE	Forge Global	0.6	90.3%	217.8%
SGML	Sigma Lithium	1.1	87.3%	-10.6%
INSP	Inspire Medical Systems	4.0	82.8%	-27.3%
NPCE	NeuroPace	0.6	77.2%	48.9%
ALMS	Alumis	0.6	71.9%	-0.3%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
UP	Wheels Up Experience	0.4	-52.7%	-62.4%
CCOI	Cogent Communications	0.9	-51.9%	-72.9%
SMR	NuScale Power	3.0	-50.7%	12.3%
FRMI	Fermi	10.3	-47.5%
AMSC	American Superconductor	1.4	-47.2%	30.1%
TLRY	Tilray Brands	7.5	-46.1%	-46.9%
BTDR	Bitdeer Technologies	2.4	-44.8%	-41.8%
EXOD	Exodus Movement	0.4	-43.1%	-53.3%
STUB	Stubhub	3.5	-39.8%
METC	Ramaco Resources	1.0	-39.4%	66.9%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

Peer Comparisons for Sight Sciences

Peers to compare with:

Financials

	SGHT	A	ATEC	CERS	AVRT	BLLN	Median
Name	Sight Sc.	Agilent .	Alphatec	Cerus	Avertix .	BillionT.
Mkt Price	8.56	149.26	21.23	1.99	-	102.76	21.23
Mkt Cap	0.4	42.4	3.2	0.4	-	-	1.8
Rev LTM	76	6,788	728	199	-	-	464
Op Inc LTM	-45	1,444	-74	-9	-	-	-27
FCF LTM	-32	1,088	-3	0	-	-	-2
FCF 3Y Avg	-38	1,308	-112	-15	-	-	-27
CFO LTM	-31	1,495	35	4	-	-	19
CFO 3Y Avg	-38	1,662	-36	-12	-	-	-24

Growth & Margins

	SGHT	A	ATEC	CERS	AVRT	BLLN	Median
Name	Sight Sc.	Agilent .	Alphatec	Cerus	Avertix .	BillionT.
Rev Chg LTM	-4.4%	4.5%	27.1%	13.0%	-	-	8.8%
Rev Chg 3Y Avg	6.1%	0.8%	31.8%	8.3%	-	-	7.2%
Rev Chg Q	-1.2%	10.1%	30.4%	14.5%	-	-	12.3%
QoQ Delta Rev Chg LTM	-0.3%	2.4%	6.7%	3.5%	-	-	2.9%
Op Mgn LTM	-59.6%	21.3%	-10.1%	-4.8%	-	-	-7.4%
Op Mgn 3Y Avg	-66.1%	21.5%	-21.8%	-11.9%	-	-	-16.8%
QoQ Delta Op Mgn LTM	4.2%	-0.1%	3.8%	1.3%	-	-	2.6%
CFO/Rev LTM	-41.2%	22.0%	4.8%	1.8%	-	-	3.3%
CFO/Rev 3Y Avg	-47.0%	24.6%	-7.6%	-7.5%	-	-	-7.6%
FCF/Rev LTM	-41.6%	16.0%	-0.5%	0.1%	-	-	-0.2%
FCF/Rev 3Y Avg	-47.6%	19.4%	-21.7%	-9.7%	-	-	-15.7%

Valuation

	SGHT	A	ATEC	CERS	AVRT	BLLN	Median
Name	Sight Sc.	Agilent .	Alphatec	Cerus	Avertix .	BillionT.
Mkt Cap	0.4	42.4	3.2	0.4	-	-	1.8
P/S	2.4	4.9	3.0	1.5	-	-	2.7
P/EBIT	-4.4	22.2	-19.2	-42.1	-	-	-11.8
P/E	-3.9	27.5	-14.2	-19.1	-	-	-9.1
P/CFO	-5.8	22.4	62.8	85.5	-	-	42.6
Total Yield	-25.6%	4.5%	-7.0%	-5.2%	-	-	-6.1%
Dividend Yield	0.0%	0.8%	0.0%	0.0%	-	-	0.0%
FCF Yield 3Y Avg	-20.1%	3.7%	-11.2%	-5.1%	-	-	-8.1%
D/E	0.2	0.1	0.3	0.3	-	-	0.2
Net D/E	-0.3	0.1	0.2	0.1	-	-	0.1

Returns

	SGHT	A	ATEC	CERS	AVRT	BLLN	Median
Name	Sight Sc.	Agilent .	Alphatec	Cerus	Avertix .	BillionT.
1M Rtn	67.8%	3.2%	10.1%	30.9%	-	-	20.5%
3M Rtn	125.3%	19.4%	33.5%	51.9%	-	-	42.7%
6M Rtn	101.9%	30.4%	72.9%	38.2%	-	-	55.5%
12M Rtn	121.8%	8.0%	112.3%	12.4%	-	-	62.4%
3Y Rtn	-28.2%	-2.0%	106.7%	-52.0%	-	-	-15.1%
1M Excs Rtn	67.9%	3.2%	10.1%	31.0%	-	-	20.5%
3M Excs Rtn	124.1%	11.1%	22.9%	44.3%	-	-	33.6%
6M Excs Rtn	87.2%	15.7%	58.2%	23.5%	-	-	40.8%
12M Excs Rtn	101.0%	-4.5%	89.0%	-6.0%	-	-	42.3%
3Y Excs Rtn	-91.3%	-72.6%	50.7%	-119.0%	-	-	-82.0%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/6/2025	3/7/2025	3/13/2024	3/16/2023	3/24/2022	7/15/2021	7/15/2021
Key Financials
Total Revenue	76	80	81	71	49	28	23
EBITDA	-41	-46	-49	-81	-58	-32	-24
Operating Income	-45	-51	-57	-84	-51	-32	-24
Net Income	-46	-52	-56	-86	-63	-35	-26
EPS	-0.90	-1.03	-1.14	-1.80	-2.36	-0.99	-0.80
Growth Rates
Total Revenue Growth	-4.4%	-1.5%	13.6%	45.7%	77.1%	18.4%	210.1%
EBITDA Growth	9.2%	7.1%	39.0%	-40.2%	-82.4%	-34.2%	-65.8%
Operating Income Growth	8.8%	11.8%	31.8%	-63.1%	-59.9%	-33.9%	-68.1%
Net Income Growth	8.4%	7.3%	35.6%	-37.0%	-81.5%	-34.1%	-81.0%
Margins
EBITDA Margin	-53.3%	-57.5%	-61.0%	-113.6%	-118.0%	-114.6%	-101.1%
Operating Income Margin	-59.6%	-63.3%	-70.7%	-117.7%	-105.2%	-116.5%	-103.0%
Net Income Margin	-60.6%	-64.5%	-68.5%	-120.9%	-128.6%	-125.5%	-110.8%
Cash & Debt
Total Cash	92	120	138	185	261	62	21
Total Debt	41	40	35	35	34	32	14
Net Debt / (Cash)	-52	-80	-103	-150	-226	-29	-7
Cash Flows
Net Cash from Operations	-31	-22	-47	-76	-53	-32	-25
Free Cash from Operations	-32	-23	-48	-77	-53	-33	-26
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/6/2025	8/7/2025	5/8/2025	3/7/2025	11/7/2024	8/2/2024	5/6/2024	3/13/2024	11/7/2023	8/7/2023	5/8/2023	3/16/2023
Key Financials Quarterly
Total Revenue	20	20	18	19	20	21	19	19	20	23	19	21
Ebitda	-7	-10	-13	-10	-10	-11	-15	-9	-11	-13	-16	-16
Operating Income	-8	-12	-14	-12	-11	-13	-15	-11	-13	-15	-18	-17
Net Income	-8	-12	-14	-12	-11	-12	-16	-11	-13	-15	-17	-17
EPS	-0.16	-0.23	-0.28	-0.23	-0.22	-0.25	-0.33	-0.22	-0.27	-0.30	-0.35	-0.35
Key Financials TTM
Total Revenue TTM	76	76	78	80	80	79	81	81	83	82	75	71
Ebitda TTM	-41	-43	-44	-46	-45	-46	-49	-49	-56	-65	-75	-81
Operating Income TTM	-45	-49	-50	-51	-50	-52	-54	-57	-63	-72	-79	-84
Net Income TTM	-46	-49	-49	-52	-50	-52	-55	-56	-62	-71	-80	-86
Growth Rates Quarterly
Total Revenue Growth	-1.2%	-8.5%	-9.1%	1.7%	0.7%	-9.0%	2.3%	-8.7%	7.1%	36.2%	26.5%	39.9%
EBITDA Growth	28.7%	4.5%	14.5%	-14.2%	15.6%	17.1%	5.0%	40.9%	45.6%	41.3%	29.0%	-6.4%
Operating Income Growth	29.6%	7.8%	5.9%	-7.4%	16.3%	16.7%	16.2%	34.9%	38.6%	33.6%	20.8%	-15.9%
Net Income Growth	26.2%	3.1%	13.0%	-10.8%	15.1%	16.4%	4.7%	36.8%	41.4%	38.1%	26.6%	-6.1%
Margins Quarterly
EBITDA Margin	-34.3%	-53.6%	-72.5%	-54.9%	-47.6%	-51.4%	-77.1%	-48.9%	-56.8%	-56.4%	-83.0%	-75.6%
Operating Income Margin	-39.7%	-59.6%	-79.2%	-62.5%	-55.7%	-59.2%	-76.4%	-59.3%	-67.0%	-64.7%	-93.3%	-83.0%
Net Income Margin	-41.0%	-61.0%	-80.8%	-62.1%	-54.9%	-57.7%	-84.4%	-57.0%	-65.1%	-62.9%	-90.7%	-82.3%
Cash & Debt
Total Cash	92	102	109	120	119	118	127	138	145	155	167	185
Total Debt	41	41	40	40	35	35	35	35	35	35	35	35
Net Debt / (Cash)	-52	-61	-68	-80	-83	-83	-92	-103	-110	-120	-132	-150
Cash Flows Quarterly
FCF from Operations	-9	-8	-12	-3	0	-9	-10	-6	-10	-13	-17	-16
Cash Flows TTM
FCF from Operations TTM	-31	-22	-24	-22	-25	-36	-40	-47	-56	-67	-71	-76
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-8.0%	-12.2%	-15.0%	-13.5%	-13.0%	-14.8%	-18.0%	-14.2%	-17.8%	-21.1%	-26.0%	-27.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-11.5%	-12.8%	-13.4%	-14.3%	-14.4%	-15.2%	-16.6%	-18.3%	-21.0%	-24.9%	-29.4%	-33.7%

Price Behavior

Price Behavior

Market Price	$8.56
Market Cap ($ Bil)	0.4
First Trading Date	07/15/2021
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$5.34	$3.85
DMA Trend	up	up
Distance from DMA	60.2%	122.2%
	3M	1YR
Volatility	100.1%	81.7%
Downside Capture	177.93	142.65
Upside Capture	510.95	203.56
Correlation (SPY)	37.1%	33.4%

SGHT Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	4.03	3.14	3.07	3.24	1.38	1.66
Up Beta	1.55	0.86	2.32	3.05	1.59	1.37
Down Beta	5.13	3.83	2.87	2.84	0.37	1.40
Up Capture	1126%	1031%	742%	749%	431%	873%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	12	22	27	55	108	348
Down Capture	199%	94%	178%	230%	129%	111%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	18	32	62	130	380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

null

Based On 5-Year Data

null

Based On 10-Year Data

null

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	905,132
Short Interest: % Change Since 10312025	-6.2%
Average Daily Volume	306,176
Days-to-Cover Short Interest	2.96
Basic Shares Quantity	52,377,805
Short % of Basic Shares	1.7%

Returns Analyses

	Title
0	Would You Still Hold Sight Sciences Stock If It Fell 30%?

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11062025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	5082025	10-Q 3/31/2025
12312024	3072025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8022024	10-Q 6/30/2024
3312024	5062024	10-Q 3/31/2024
12312023	3132024	10-K 12/31/2023
9302023	11072023	10-Q 9/30/2023
6302023	8072023	10-Q 6/30/2023
3312023	5082023	10-Q 3/31/2023
12312022	3162023	10-K 12/31/2022
9302022	11102022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	5102022	10-Q 3/31/2022
12312021	3242022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Taylor Brenton	EVP, Operations & R&D	11182025	Sell	7.06	14,418	101,791	1,206,067	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Sight Sciences (SGHT)

Market Price (12/4/2025): $8.42 | Market Cap: $441.0 MilSector: Health Care | Industry: Life Sciences Tools & Services

Sight Sciences (SGHT)

Market Price (12/4/2025): $8.42Market Cap: $441.0 MilSector: Health CareIndustry: Life Sciences Tools & Services

Valuation, Metrics & Events

SGHT Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Sight Sciences (SGHT)

Surgical Glaucoma Products (OMNI Surgical System, SION Surgical Instrument)

Dry Eye Disease Products (TearCare System)

Interactive Breakdown

Better Bets than Sight Sciences (SGHT)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sight Sciences

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/4/2025): $8.42 | Market Cap: $441.0 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/4/2025): $8.42
Market Cap: $441.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services